What it sells
Survival predictions from radiology scans for cancer trials.
Business model breakdown
Buyer: who owns the budget?
Biopharma companies and clinician scientists.
Workflow: what inputs become what output?
Index: upload de-identified DICOM imaging to the platform with automatic QC; Inference: models generate IPRO scores for baseline/follow-up scans; Optimize: feed results into statistical analyses for trial design and reimbursement strategy.
Distribution: how it reaches customers
Demo-led: schedule a demo by email.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-21 | Series A | $25M | OrbiMed, Qiming | betakit.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.